Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

Journal of Infectious Diseases

Volumn 177, Issue 2, 1998, Pages 467-469

  Groothuis, Jessie R ^a   King, Susan J ^b   Hogerman, Debbie A ^b   Paradiso, Peter R ^b   Simoes, Eric A F ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DROWSINESS; DRUG SAFETY; ERYTHEMA; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTIOUS COMPLICATION; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; IRRITABILITY; LUNG DYSPLASIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; SEIZURE; URTICARIA; VACCINATION; VOMITING;

EID: 0031906484     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517377     Document Type: Article

References (14)

1. Morris JA, Blount RE, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956;92:544-9.
2. Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957;66:291-300.
3. Beem M, Wright RH, Hamre D, Egerer R, Oehme M. Association of the chimpanzee coryza agent with acute respiratory disease in children. N Engl J Med 1960;263:523-30.
4. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
5. Groothuis JR, Salbenblatt CK, Lauer BA. Severe respiratory syncytial virus infection in older children. Am J Dis Child 1990;144:346-8.
6. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
7. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34.
8. Belshe RB, Anderson EL, Walsh EE. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993;168:1024-9.
9. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hilderth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993;167:191-5.
10. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996;15:23-31.
11. Paradiso PR, Hildereth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994;13:792-8.
12. Prince GA, Hemming VG, Horsewood RC, Baron PA, Murphy BR, Chanock RM. Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 1990;64:3091-2.
13. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl J Med 1993;329:1524-30.
14. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996;14:1214-8.